Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Black Diamond Therapeutics plans a webcast fireside chat and investor meetings at the H.C. Wainwright Global Investment Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Black Diamond Therapeutics (BDTX)/b) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York, NY.The session featuring Chief Scientific Officer Elizabeth Buck, Ph.D., is scheduled for 10:00–10:30 a.m. ET. A live webcast and 90-day replay will be available under “Events and Presentations” in the Investors section of the company’s website. The company will also host one-on-one investor meetings that day.
Details
News Market Reaction – BDTX
On Sep 3, the first trading day after this news, BDTX closed 1.87% below the previous close. Relative volume reached 3.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Conference edition
- 28th
- H.C. Wainwright Global Investment Conference
- Conference date
- September 15, 2026
- Fireside chat and investor meetings
- Presentation time
- 10:00-10:30am ET
- September 15, 2026 presentation
- Webcast replay period
- 90 days
- Following the event
Historical Context
-
Reported clinical progress and cash runway extending into the second half of 2028
-
Announced CEO fireside chat at the Jefferies Global Healthcare Conference
-
Reported positive silevertinib results in frontline EGFR-mutant NSCLC
-
Scheduled webcast highlighting updated Phase 2 silevertinib results
-
Reported first-quarter results and provided a corporate development update
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
oncogenic mutations medical
brain-penetrant medical
egfr inhibitor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York, NY. In addition, the Company will host one-on-one meetings with investors on the same day.
Presentation details are as follows:
- 10:00-10:30am ET on Tuesday, September 15
The Webcast will be available at the start of the presentation under “Events and Presentations” on the Investors section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
About Silevertinib
Silevertinib is an investigational oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that has demonstrated best-in-class CNS activity, selectively targeting classical and more than 50 non-classical EGFR mutations in NSCLC. It is also designed to potently inhibit key EGFR alterations seen in GBM, including EGFRvIII, while avoiding the paradoxical EGFR activation reported with reversible TKIs. To date, over 200 patients with EGFRm NSCLC or EGFR-altered GBM have been treated with silevertinib.
In addition to the ongoing Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, the Company also initiated a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM (NCT07326566) in May 2026.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
investors@bdtx.com
For Media:
media@bdtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Black Diamond Therapeutics (BDTX) present at the H.C. Wainwright 28th Annual Global Investment Conference?
Black Diamond Therapeutics is scheduled for a fireside chat on Tuesday, September 15, 2026, from 10:00–10:30 a.m. ET during the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.
How can investors access the Black Diamond Therapeutics (BDTX) webcast from the H.C. Wainwright conference?
The live webcast will be available at the start of the presentation under “Events and Presentations” in the Investors section of Black Diamond Therapeutics’ website. A replay will be archived and accessible for 90 days following the event.
Will Black Diamond Therapeutics (BDTX) hold investor meetings at the H.C. Wainwright 2026 conference?
Yes. On September 15, 2026, Black Diamond Therapeutics will host one-on-one meetings with investors in addition to its scheduled fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference.